UNSPSC 51334415: Rilapine

This classification denotes an antipsychotic agent with the molecular formula C22H20ClN3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7QCG0RP106, chemically known as (z)-2-chloro-10-(4-methyl-1-piperazinyl)-5h-dibenzo(a,d)cycloheptene-(delta(sup 5,alpha))-acetonitrile but generally known as rilapine, which bears US NIH Compound Identifier 6446980. European Medicines Agency schedules Rilapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10313MIG.

UNSPSC 51334415 Rilapine is a Commodity code that captures pharmaceutical product procurement by state and local health agencies, though recent solicitations under this code span a broader range of pharmaceutical and therapeutic products — naloxone, generic multi-source pharmaceuticals, and pharmacy benefit program administration — rather than rilapine specifically. State and local buyers under this code include county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple jurisdictions. The scope of work ranges from direct purchase of emergency-response medications and over-the-counter products through authorized wholesaler networks to exploratory vendor engagement for direct-to-manufacturer prescription programs designed to optimize cost and fulfillment efficiency.

Recent activity shows Seminole County, Florida procuring 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding (IFB 60459723LAS, response deadline July 26, 2023), while the Texas Health and Human Services Commission issued a Request for Information on a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program (RFI HHS0017013, April 3, 2026) to explore vendor capabilities for direct state contracting outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, has issued an RFP for generic multi-source pharmaceuticals and OTC products serving participating state and local government facilities including Oregon (RFP S1070000015802, proposals due March 26, 2026, with awards effective July 1, 2026). Geographic activity centers on Florida, Texas, Minnesota, and Oregon, with procurement occurring through both individual county IFBs and multi-state cooperative vehicles. MMCAP's cooperative structure and Texas HHS's exploratory RFI suggest that pharmaceutical procurement at the state and local level is increasingly coordinated through purchasing alliances and direct-to-manufacturer pathways rather than solely through traditional wholesale channels.